295 related articles for article (PubMed ID: 33860709)
21. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre
Egerton A; Broberg BV; Van Haren N; Merritt K; Barker GJ; Lythgoe DJ; Perez-Iglesias R; Baandrup L; Düring SW; Sendt KV; Stone JM; Rostrup E; Sommer IE; Glenthøj B; Kahn RS; Dazzan P; McGuire P
Mol Psychiatry; 2018 Nov; 23(11):2145-2155. PubMed ID: 29880882
[TBL] [Abstract][Full Text] [Related]
22. Anterior Hippocampal-Cortical Functional Connectivity Distinguishes Antipsychotic Naïve First-Episode Psychosis Patients From Controls and May Predict Response to Second-Generation Antipsychotic Treatment.
Blessing EM; Murty VP; Zeng B; Wang J; Davachi L; Goff DC
Schizophr Bull; 2020 Apr; 46(3):680-689. PubMed ID: 31433843
[TBL] [Abstract][Full Text] [Related]
23. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.
Gunasekera B; Wilson R; O'Neill A; Blest-Hopley G; O'Daly O; Bhattacharyya S
Psychol Med; 2023 Jul; 53(10):4732-4741. PubMed ID: 35775365
[TBL] [Abstract][Full Text] [Related]
24. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
Bhattacharyya S; Wilson R; Appiah-Kusi E; O'Neill A; Brammer M; Perez J; Murray R; Allen P; Bossong MG; McGuire P
JAMA Psychiatry; 2018 Nov; 75(11):1107-1117. PubMed ID: 30167644
[TBL] [Abstract][Full Text] [Related]
25. A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia.
Kraguljac NV; Morgan CJ; Reid MA; White DM; Jindal RD; Sivaraman S; Martinak BK; Lahti AC
Schizophr Res; 2019 Aug; 210():239-244. PubMed ID: 30630705
[TBL] [Abstract][Full Text] [Related]
26. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.
Hahn B
Schizophr Bull; 2018 Jan; 44(1):46-53. PubMed ID: 29083450
[TBL] [Abstract][Full Text] [Related]
27. Hippocampal subregion volume changes associated with antipsychotic treatment in first-episode psychosis.
Rhindress K; Robinson DG; Gallego JA; Wellington R; Malhotra AK; Szeszko PR
Psychol Med; 2017 Jul; 47(10):1706-1718. PubMed ID: 28193301
[TBL] [Abstract][Full Text] [Related]
28. A systematic review of the antipsychotic properties of cannabidiol in humans.
Iseger TA; Bossong MG
Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
[TBL] [Abstract][Full Text] [Related]
29. Cannabidiol versus placebo as adjunctive treatment in early psychosis: study protocol for randomized controlled trial.
Dixon T; Cadenhead KS
Trials; 2023 Nov; 24(1):775. PubMed ID: 38037108
[TBL] [Abstract][Full Text] [Related]
30. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
31. Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.
de la Fuente-Sandoval C; Reyes-Madrigal F; Mao X; León-Ortiz P; Rodríguez-Mayoral O; Solís-Vivanco R; Favila R; Graff-Guerrero A; Shungu DC
Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv105. PubMed ID: 26364273
[TBL] [Abstract][Full Text] [Related]
32. The impact of cannabidiol treatment on resting state functional connectivity, prefrontal metabolite levels and reward processing in recent-onset patients with a psychotic disorder.
van Boxel R; Gangadin SS; Janssen H; van der Steur S; van der Vinne LJC; Dortants L; Pelgrim TAD; Draisma LWR; Tuura R; van der Meer P; Batalla A; Bossong MG
J Psychiatr Res; 2023 Jul; 163():93-101. PubMed ID: 37207437
[TBL] [Abstract][Full Text] [Related]
33. Glutamate levels in the anterior cingulate cortex in un-medicated first episode psychosis: a proton magnetic resonance spectroscopy study.
Borgan FR; Jauhar S; McCutcheon RA; Pepper FS; Rogdaki M; Lythgoe DJ; Howes OD
Sci Rep; 2019 Jul; 9(1):8685. PubMed ID: 31266965
[TBL] [Abstract][Full Text] [Related]
34. Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic (1)NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia.
Strzelecki D; Podgórski M; Kałużyńska O; Gawlik-Kotelnicka O; Stefańczyk L; Kotlicka-Antczak M; Gmitrowicz A; Grzelak P
Neurosci Lett; 2015 Oct; 606():7-12. PubMed ID: 26306650
[TBL] [Abstract][Full Text] [Related]
35. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol.
Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Zelaya F; Allen P; Brammer M; Perez J; McGuire P; Bhattacharyya S
Psychol Med; 2024 Apr; 54(5):993-1003. PubMed ID: 37845827
[TBL] [Abstract][Full Text] [Related]
36. Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.
de Bartolomeis A; Sarappa C; Magara S; Iasevoli F
Eur J Pharmacol; 2012 May; 682(1-3):1-11. PubMed ID: 22387855
[TBL] [Abstract][Full Text] [Related]
37. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study.
Wood SJ; Kennedy D; Phillips LJ; Seal ML; Yücel M; Nelson B; Yung AR; Jackson G; McGorry PD; Velakoulis D; Pantelis C
Neuroimage; 2010 Aug; 52(1):62-8. PubMed ID: 20399273
[TBL] [Abstract][Full Text] [Related]
38. Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals.
Velakoulis D; Wood SJ; Wong MT; McGorry PD; Yung A; Phillips L; Smith D; Brewer W; Proffitt T; Desmond P; Pantelis C
Arch Gen Psychiatry; 2006 Feb; 63(2):139-49. PubMed ID: 16461856
[TBL] [Abstract][Full Text] [Related]
39. Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naïve ultra-high-risk subjects and first-episode schizophrenia.
Nenadic I; Maitra R; Basu S; Dietzek M; Schönfeld N; Lorenz C; Gussew A; Amminger GP; McGorry P; Reichenbach JR; Sauer H; Gaser C; Smesny S
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1661-8. PubMed ID: 26088723
[TBL] [Abstract][Full Text] [Related]
40. Striatal glutamate, subcortical structure and clinical response to first-line treatment in first-episode psychosis patients.
Reyes-Madrigal F; Guma E; León-Ortiz P; Gómez-Cruz G; Mora-Durán R; Graff-Guerrero A; Kegeles LS; Chakravarty MM; de la Fuente-Sandoval C
Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar; 113():110473. PubMed ID: 34748864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
